◼ Archived
Business
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
2 trends tracked about this subject — the full history, oldest to newest below.
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.